Category: Uncategorized

Orbit Genomics today announced that it is the grand prize winner of the Startup Prize Focus on Health 2025 in the Non-FDA track, a nationally recognized competition spotlighting transformative innovation in healthcare and life sciences. Selected from a record-breaking pool of 75 startups across 23 states, Orbit Genomics was recognized for its patented OrbiSeq™ platform,…

Orbit Genomics, a pioneer in redefining precision medicine, today announced the appointment of Angie Purvis as Laboratory Director. With over 15 years of leadership in high-complexity molecular, immunological, and clinical chemistry laboratories, Purvis brings deep expertise in laboratory-developed tests (LDTs), regulatory compliance, and diagnostic innovation to the Orbit team. “Angie’s track record in building high-quality,…

Orbit Genomics, a pioneer in redefining precision medicine, today announced the appointment of Vern Norviel, JD, MS, to its Advisory Board. A highly respected attorney and strategist in biotechnology and intellectual property law, Norviel brings decades of experience advising companies and investors at the forefront of life science innovation. “Vern’s rare ability to blend deep…

Orbit Genomics is proud to announce that we have been named a finalist in the Startup Prize Focus on Health competition, an initiative that spotlights transformative innovation in healthcare and life sciences. This recognition highlights the impact and potential of our patented OrbiSeq™ platform, an AI-powered approach to transform diagnosis, treatment and prevention of complex…

Orbit Genomics, a pioneer in redefining precision medicine, today announced the appointment of Julie Silber to its Board of Directors. Silber brings over 25 years of experience in investor relations, capital markets, corporate strategy, and board advisory, with expertise in the diagnostics and life sciences sectors to support Orbit’s next phase of growth in precision…

Orbit Genomics thanks the MassChallenge community for an incredible Midpoint Road Show in Dallas last week! The energy, insight, and support from mentors and partners was invaluable—but what stood out most was the camaraderie among the cohort.We are surrounded by an inspiring group of founders who are each tackling MASSive problems in healthcare—from early cancer…

Orbit Genomics, Inc. has been named one of the 30 finalists for the Pepperdine Most Fundable Companies Competition, chosen from over 2,300 applicants.  We would like to thank Pepperdine and the judges for this competition in recognizing the company for its efforts in developing highly accurate genomics tests for oncology, cardiovascular, longevity and other indications.…

Orbit Genomics was awarded a two-year $2MM Direct to Phase II SBIR Grant from NIH/NCI to develop the second-generation of our lung cancer test, OrbiSeq-L. OrbiSeq-L, is a simple blood test that diagnoses lung cancer in patients that have low-dose CT scans with indeterminate pulmonary nodules, IPNs. Every year, 2.5-3 million Americans have low-dose CT…

Orbit Genomics is proud to attend the graduation of the CancerX Accelerator’s inaugural cohort. We were selected from over 100 startup applicants to participate in this year’s program which included months of mentorship, hands-on learning at the Moffit Cancer Center, and many professional sessions with Champions. We look forward to continue strengthening the relationships with…